Telocyte | HomePage

Telocyte focuses on the
development of telomerase therapy
to treat Alzheimer's
disease.

Alzheimer’s & Dementia: the Journal of the Alzheimer’s Association, published our latest paper, explaining how Alzheimer’s works and how Telocyte plans to cure it. It was describes as "the most important paper every published" on Alzheimer's disease.

Request a copy HERE

Telocyte seeks to cure Alzheimer's differently

Prior therapies have focused on effects, not on causes. They have tried to help symptoms or wished to remove amyloid or tau proteins.

Research shows that cell aging triggers the gradual accumulation of amyloid, as well as the loss of neurons that defines Alzheimer’s.

Telomerase resets the abnormal pattern of gene expression that results in Alzheimer’s disease. We can make a difference. Join us.

Our Mission

Our mission is not to help anyone “live with Alzheimer’s”, but to ensure that all of us can live without Alzheimer’s. Our mission is to cure Alzheimer’s, plain and simple. We intend to save the lives, the minds, and the presence of those who have Alzheimer’s now and to prevent anyone from getting Alzheimer’s in future.

Learn more

This is Iris, the mother of our CEO and catalyst for the founding of Telocyte.

We would like to acknowledge the wonderful care and support for Iris
provided by the staff and friends at The Foundation of Lady Katherine Leveson, Temple Balsall, in the UK.

Farewell Iris, you always lead by example, facing adversity with good humour and a resolve to overcome.

As a dedicated nurse, she helped many during her life, her simple request to us was that we should find
a future beyond Alzheimer’s for others.

That is our intention.

Introducing Telocyte's founders

Michael Fossel, MD, PhD
Founder, President
Dr. Fossel is the driving force behind Telocyte and has been the leader in proposing the use of telomerase to treat human disease for the past two decades.
Read more

Peter Rayson
Founder, Chief Executive Officer
Peter T. Rayson is an experienced industry executive who provides leadership and business acumen for Telocyte.
Read more

Telocyte and CNIO

Telocyte and CNIO will be collaborating to take Telomerase Therapy to FDA human trials.

Under the direction of Dr. Maria Blasco, C.N.I.O. – The Spanish National Research Centre, has recently made advances in both animal research and delivery systems that has facilitated an opportunity to pursue unsurpassed clinical advances in the field of telomerase therapy. Dr. Blasco is an internationally recognized expert in the field of telomerase

Michael Fossel Book and Research

The Telomerase Revolution
Meant for the general public, this book describes what we know about aging—and how to prevent and reverse age-related diseases using telomerase therapy.
Buy the book

Cells, Aging, and Human Disease
Cells, Aging, and Human Disease (Oxford University Press) is the first textbook to explore aging all the way from genes to clinical application, analyzing the fundamental cellular changes which underlie human age-related disease.

Cells, Aging, and Human Disease (Oxford University Press) is the first textbook to explore aging all the way from genes to clinical application, analyzing the fundamental cellular changes which underlie human age-related disease. With over 4,000 references, this text explores both the fundamental processes of human aging and the tissue-by-tissue pathology, detailing both breaking research and current state-of-the-art clinical interventions in aging and age-related disease.

Far from merely sharing a common onset late in the lifespan, age-related diseases are linked by fundamental common characteristics at the genetic and cellular levels. Emphasizing human cell mechanisms, the first section presents and analyzes our current knowledge of telomere biology and cell senescence. In superb academic detail, the text brings the reader up to date on telomere maintenance, telomerase dynamics, and current research on cell senescence--and the general model--cell senescence as the central component in human senescence and cancer. For each human malignancy, the chapter reviews and analyzes all available data on telomeres and telomerase, as well as summarizing current work on their clinical application in both diagnosis and cancer therapy.

The second edition, oriented by organs and tissues, explores the actual physiological impact of cell senescence and aging on clinical disease. After a summary of the literature on early aging syndromes--the progerias--the text reviews aging diseases (Alzheimer's dementia, osteoarthritis, atherosclerosis, immune aging, presbyopia, sarcopenia, etc.) in the context of the tissues in which they occur. Each of the ten clinical chapters--skin, cardiovascular system, bone and joints, hematopoietic and immune systems, endocrine, CNS, renal, muscle, GI, and eyes--examines what we know of their pathology, the role of cell senescence, and medical interventions, both current and potential.
Read MoreLess Buy the book

IdeaCity
In 2014, Dr. Fossel gave this short (17-minute) talk at IdeaCity, giving a clear and concise presentation of the rationale for and the history of telomerase therapy, as well as the plans for human trials.
Read more